Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2000 June;46(2) > Minerva Gastroenterologica e Dietologica 2000 June;46(2):81-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Gastroenterologica e Dietologica 2000 June;46(2):81-6

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Therapy for chronic hepatitis C (Present status)

Rizzetto M.


PDF


Interferon (IFN) is the only treatment so far approved world-wide for chronic hepatitis C. Though proof of long term benefit is lacking, metanalyses have provided extrapolations that substantiate the hypothesis that this therapy can modify favourably the natural history of the disease. Results, however, are limited and new forms of therapy, complementary or alternative to IFN, have been developed. Efforts to ameliorate the results of alfa-IFN mono therapy in chronic hepatitis C with new IFNs, or the manipulation of IFN monotherapy so as to obtain the maximum results compatible with tolerance, have not produced a better results than the classical protocols of alfa IFN monotherapy. Important recent therapeutic progress that surpasses and advances the results obtained with single IFN therapy is the combination of IFN with ribavirin, with which overall rates of response have increased three times compared to IFN monotherapy. Combination therapy has become the treatment of choice for IFN naive patients as well as for IFN relapses; it is not efficacious in patients who have not responded to IFN.

top of page